Biomarin以4.8B美元购买Amicus Amicus, 获得罕见疾病药物和美国对第三阶段候选者的权利。 BioMarin to buy Amicus for $4.8B, gaining rare disease drugs and U.S. rights to a Phase 3 candidate.

生物马林制药公司同意在48亿美元的全部现金交易中购买Amicus治疗药品,每股支付14.50美元,这是对Amicus最近股价的重大溢价。 BioMarin Pharmaceutical has agreed to acquire Amicus Therapeutics in a $4.8 billion all-cash deal, paying $14.50 per share, a significant premium to Amicus’s recent stock prices. 这项交易有待股东和监管机构批准,预计将在2026年第二季度结束。 The transaction, pending shareholder and regulatory approval, is expected to close in the second quarter of 2026. 收购增加了两种罕见疾病治疗方法 - - 对于法布里病的Galafold和Pombiliti以及Pompe病的Opfolda - - 进入BioMarin的产品组合,以及对DMX-200的美国权利,这是一种治疗罕见脏疾病的第三阶段药物. The acquisition adds two rare disease treatments—Galafold for Fabry disease and Pombiliti plus Opfolda for Pompe disease—to BioMarin’s portfolio, along with U.S. rights to DMX-200, a Phase 3 drug for a rare kidney disorder. 这笔交易预计将加强BioMarin在罕见疾病方面的商业存在。 The deal is expected to strengthen BioMarin’s commercial presence in rare diseases.